Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

Illumina will fight the suit, arguing it’s giving competitors a fair deal and benefitting the field as a whole

Illumina will fight the suit, arguing it’s giving competitors a fair deal and benefitting the field as a whole.

The FTC’s 4-0 vote to challenge Illumina’s pending $7.1 billion Grail acquisition aligns with acting agency Chair Rebecca Kelly Slaughter’s vow to expand scrutiny of biotech M&A beyond